IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Chen et al.

Serial No.

10/511,636

Filed: October 18, 2004

Ophthalmic Compositions for Treating Ocular For:

Hypertension

Art Unit: 1618	
----------------	--

Examiner:

To be Assigned

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Supplemental

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

Computer generated form "IDS Letter" (IDS Folder), Merck & Co., Inc., 09/08/2005

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CAS	
		ļ <u></u> -	
		<u> </u>	

If th	is is inconvenient, additional copies will be submitted upon reques	t.	
6	6. In accordance with 37 C.F.R. 1.97, (check one)		
	the attached information is filed within three months of the filing da	te of the captioned case.	
\checkmark	the attached information is filed more than three months after the f Office Action on the merits.	iling date but prior to the m	ailing of a first
	the attached information is filed before the mailing of a first Office a examination under §1.114.	action after the filing of a re	quest for continued
	the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final Action otherwise closes prosecution in the application. The enclosed aut Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).	action, Notice of Allowance horization is therefore give	, or an action that
	each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application not Statement.		
	each item of information contained in the information disclosure st from a foreign patent office in a counterpart application and this co designated in §1.56(c) more than thirty days prior to the filing of the	mmunication was not rece	ived by any individual
	no item of information contained in this Information Disclosure Sta foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual designanths prior to the filing of this Statement.	e knowledge of the person	signing the certification
		Respectfully submitted	

By: Sylvia/A. Ayler
Attorney For Applicant(s)

Reg. No. 36,436 MERCK & CO., INC. Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907 (732)594-4909

Date: July 26, 2006

			<u> </u>	Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE		
Substitute for form 1449A/PTO			COMPLETE IF KNOWN			
" I	NFORMATION I	DISCLOSURE	Application Number	10/511,636		
	TO A TOTAL MEDIANT TO NO	O I P E	Filing Date	October 18, 2004		
3	TATEMENT BY		2 1 11 20 1 (111111111111111111111111111	Chen et al.		
		JUL 3 1 2006	رير Group Art Unit	1618		
	(use as many sheets	manager (Examiner Name	To be Assigned		
Sheet	1	of 2	Attorney Docket Number	21101YP		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Number Code		U.S. Patent Document			
		4 021 448		Bell et al.	05/03/1977		
		3 856 967		Allais et al.	12/24/1974		
		3 557 142		Bell et al.	01/19/1971		
	_		<u> </u>				

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite		Foreign Patent Document		Name of Patentee or Applicant	Date of Publication of		
Initials*	No.	Office	Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY		
		2	306 690		Synthelabo	11/05/1996		
5		W	VO 99/28297		Boehringer	06/10/1999		
		W	VO 92/04321		Rhone-Poulenc	03/19/1992		
		2	375 864		Roussel-Uclaf	07/28/1978		
		2	338 702		Roussel-Uclaf	08/19/1977		
	·	2	318 629		Roussel-Uclaf	02/18/1977		

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO				COMPLETE IF KNOWN			
INFORMATION DISCLOSURE		Application Number	10/511,636				
STATEMENT BY APPLICANT			DI ICANT	Filing Date	October 18, 2004		
3	STATEMENT BY APPLICANT			First Named Inventor	Chen et al.		
			,	Group Art Unit	1618		
(use as many sheets as necessary)		Examiner Name	To be Assigned				
Sheet	2	of	2	Attorney Docket Number	21101YP		

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Chan et al., "Structure-Activity Relationships Study of 2 Series of Leukotriene b1 Antagonists", 1996, pg. 3756-3768, Vol. 39, No. 19, J. of Medicinal Chemistry.
		Allais et al., "Recherche d' Analgesiques non Narcotiques et d' Antiinflammatoires Dans La Serie Des Carboxyalcoyl-1 Acyl-3 Indoles", 1975, pgs. 187-199, Vol. 10, No. 2, Freditions Scientifique Elsevier.
		Sheppard et al., "3-(2-(3-Pyridinyl-thiazolidin-4-oyl)Indol es, A novel Series of Platelet Activating Factor Antagonists", 1994, pg. 2011-2032, J. of Medicinal Chemistry.
		Curtin et al., "Discovery an Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Facotr Antagonists", 1988, pg. 74-75, J. of Medicinal Chemistry.
		Doebel et al., "Derivatives of Indole-1-Acetic Acid as Antiinflammatory Agents", 1972, pg. 1081-1082, J. of Medicinal Chemistry.
		· .

	Examiner Signature		Date Considered	-	
--	-----------------------	--	--------------------	---	--